Gilead Sciences, Inc. (GILD) to Distribute Quarterly Dividend of $0.82 on September 29th

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, July 28th. Investors of record on Tuesday, September 15th will be given a dividend of 0.82 per share by the biopharmaceutical company on Tuesday, September 29th. This represents a c) annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th.

Gilead Sciences has raised its dividend payment by an average of 0.0%annually over the last three years and has increased its dividend annually for the last 10 consecutive years. Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Gilead Sciences to earn $9.87 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.2%.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $143.72 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company has a market cap of $178.21 billion, a price-to-earnings ratio of -53.83 and a beta of 0.33. The stock’s 50-day moving average is $138.48 and its two-hundred day moving average is $136.29. Gilead Sciences has a 1-year low of $108.46 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the business posted $2.01 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. Analysts forecast that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider owned 118,234 shares in the company, valued at $16,273,727.76. This trade represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock worth $14,495,820 over the last three months. Company insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GILD. Bullseye Investment Management LLC acquired a new position in Gilead Sciences during the second quarter worth approximately $2,085,000. Talon Private Wealth LLC acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $212,000. Core Capital Management & Research inc. purchased a new stake in Gilead Sciences in the 2nd quarter valued at $40,000. Sequoia Financial Advisors LLC boosted its stake in Gilead Sciences by 16.9% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 58,662 shares of the biopharmaceutical company’s stock worth $7,411,000 after purchasing an additional 8,484 shares during the period. Finally, Tidal Investments LLC boosted its stake in shares of Gilead Sciences by 8.8% during the second quarter. Tidal Investments LLC now owns 545,861 shares of the biopharmaceutical company’s stock worth $68,964,000 after buying an additional 44,021 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.